The investigators combined two discovery transcriptomic datasets that compared CKD or ESRD with healthy controls. They used differential expression analysis alongside weighted gene co-expression network analysis to isolate disease-associated modules, then intersected differentially expressed genes with those modules to produce candidate lists. A protein–protein interaction network was applied and scored using Degree, Closeness, and Maximal Clique Centrality algorithms to prioritize hub genes. From these steps the study team identified ten hub genes; three were advanced for detailed evaluation: EPB42, KLF1, and H3F3A. The source did not report numerical effect sizes, p-values, or cohort sizes in the abstract and methods summary provided.
Data indicated stage-specific expression patterns among the prioritized genes. EPB42 displayed a bidirectional pattern—reduced expression in CKD versus healthy controls but increased expression in ESRD—pointing to an opposite-direction change between early and late disease states. The study team observed that KLF1 did not differ significantly between healthy controls and CKD in the analyzed datasets but showed increased expression in ESRD. H3F3A showed a monotonic increase: elevated in CKD and further elevated in ESRD. These expression trajectories were described by the authors as candidate stage-associated biomarkers that may add molecular resolution to clinical staging. The source did not provide threshold values or diagnostic performance metrics for any of the three genes.
Functional enrichment analyses of the prioritized gene sets returned processes related to oxygen transport, mitochondrial function, muscle-associated processes, and inflammation. Investigators reported that these enrichments suggest potential involvement of hypoxia-associated oxidative injury and processes related to ferroptosis. The study authors interpreted these pathways as biologically plausible contributors to renal decline, given known links between hypoxia, mitochondrial dysfunction, and progressive kidney injury. The source did not include mechanistic experiments directly demonstrating causality between these pathways and disease progression within the report.
Candidate genes were evaluated in independent GEO validation datasets drawn from the public domain. Study authors then examined expression experimentally in clinical blood samples using quantitative real-time PCR and western blotting. Those experimental assays supported the stage-associated trends reported in the discovery analyses for the prioritized genes. The authors declared ethical approval and informed consent for clinical sampling. The source text did not provide detailed descriptions of sample numbers, demographic characteristics, or assay-level thresholds in the abstract and preview material supplied.
The authors acknowledged that stage-associated molecular alterations remain incompletely characterized; the source material reflects that limitation in scope. The study relied on public transcriptomic datasets plus validation in blood samples, which raises questions about tissue specificity—transcriptomic signals derived from blood may not fully mirror intrarenal processes. The source did not report diagnostic sensitivity, specificity, or prognostic hazard estimates for the candidate markers, so clinical performance remains unquantified. Mechanistic links between the implicated pathways (hypoxia, mitochondrial dysfunction, ferroptosis) and causation of progression were proposed but not experimentally proven in the report. Future work will need to define cohort-level effect sizes, validate markers across larger and demographically diverse populations, and test whether combining these genes with clinical measures improves staging or prognosis. The source did not specify regulatory milestones or ongoing clinical trials related to these biomarkers.
Limitations in the source reporting include absence of explicit statistical metrics and cohort descriptions in the abstract; readers should consult the full preprint for methodological detail. The study provides a focused set of candidate biomarkers—EPB42, KLF1, H3F3A—and pathway leads that warrant targeted validation before they can inform diagnostic or prognostic algorithms for CKD-to-ESRD progression.